Want to see HK:6609 full AI Analyst Report?
Top Page
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
(6609)
Select Model
Select Model
Rating:73Outperform
Price Target:
HK$58.00
▲(6.23% Upside)
Action:Reiterated
Date:10/08/26
The score is primarily driven by the sharp improvement in financial performance and cash generation in 2025 alongside a low-leverage balance sheet. Technicals are supportive due to strong price trend and positive MACD, but elevated RSI points to near-term overextension risk. Valuation is moderate based on a 21.47 P/E, with no dividend yield to offset risk.
Positive Factors
Revenue Expansion
The substantial multi-year increase in revenue indicates that the company has expanded its commercial scale and market reach. A larger revenue base can improve operating leverage, support broader investment in cardiovascular technologies, and provide a stronger platform for sustained growth over the next several quarters.
Negative Factors
Profitability Volatility
Although 2025 profitability was strong, the recent history of losses means the new earnings level has not yet been demonstrated across a full operating cycle. Continued volatility could make results less predictable, complicate planning, and reduce confidence that current margins will persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Expansion
The substantial multi-year increase in revenue indicates that the company has expanded its commercial scale and market reach. A larger revenue base can improve operating leverage, support broader investment in cardiovascular technologies, and provide a stronger platform for sustained growth over the next several quarters.
Read all positive factors
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.17B
Dividend YieldN/A
Average Volume (3M)51.03K
Price to Earnings (P/E)18.1
Beta (1Y)0.84
Revenue Growth59.30%
EPS Growth131.03%
CountryHK
Employees425
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)2.48
Shares Outstanding31,565,804
10 Day Avg. Volume24,570
30 Day Avg. Volume51,032
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.61
Price to Sales (P/S)4.47
P/FCF Ratio13.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.83
Revenue Forecast (FY)HK$546.64M
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai HeartCare Medical Technology Corporation Limited is a global enterprise specializing in the research, development, manufacturing, and commercialization of neuro-interventional medical devices. Its extensive product range encompasses devic...
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
84
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 513.79M | 408.29M | 277.90M | 232.34M | 183.03M | 90.09M |
| Gross Profit | 353.55M | 272.17M | 181.72M | 151.79M | 124.33M | 54.95M |
| EBITDA | 113.69M | 72.56M | 21.87M | -68.50M | -167.31M | -183.34M |
| Net Income | 92.76M | 83.33M | -13.62M | -94.01M | -200.38M | -194.22M |
Balance Sheet | ||||||
| Total Assets | 1.37B | 1.29B | 1.21B | 1.20B | 1.31B | 1.50B |
| Cash, Cash Equivalents and Short-Term Investments | 789.70M | 786.81M | 713.72M | 721.14M | 870.12M | 1.22B |
| Total Debt | 41.22M | 42.74M | 35.75M | 36.38M | 50.69M | 41.94M |
| Total Liabilities | 152.73M | 133.50M | 144.00M | 125.60M | 147.08M | 132.10M |
| Stockholders Equity | 1.22B | 1.13B | 1.06B | 1.08B | 1.17B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | 97.61M | 139.98M | -8.39M | -137.72M | -304.01M | -260.33M |
| Operating Cash Flow | 105.51M | 154.14M | -3.23M | -88.41M | -266.77M | -205.85M |
| Investing Cash Flow | -90.02M | -253.09M | 10.80M | -125.45M | 44.84M | -161.10M |
| Financing Cash Flow | -31.71M | -44.73M | -12.38M | -21.48M | -24.75M | 821.25M |
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Technical Analysis
Positive
54.60
Price Trends
52.09
Positive
48.73
Positive
49.44
Positive
Market Momentum
-0.11
Positive
48.85
Neutral
34.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6609, the sentiment is Positive. The current price of 54.6 is above the 20-day moving average (MA) of 54.46, above the 50-day MA of 52.09, and above the 200-day MA of 49.44, indicating a neutral trend. The MACD of -0.11 indicates Positive momentum. The RSI at 48.85 is Neutral, neither overbought nor oversold. The STOCH value of 34.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6609.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$2.17B | 18.13 | 7.90% | ― | 59.30% | 131.03% | |
59 Neutral | HK$6.69B | 103.62 | 1.71% | ― | 0.75% | -20.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.63B | -0.86 | -6.69% | ― | ― | ― | |
48 Neutral | HK$2.65B | -15.75 | -7.65% | ― | 21.23% | 36.89% | |
46 Neutral | HK$11.65B | 31.22 | 6.07% | 0.06% | -3.62% | ― | |
44 Neutral | HK$432.19M | -0.78 | -28.24% | ― | -38.15% | 25.70% |
* Healthcare Sector Average
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
53.20
-1.30
-2.39%
HK:0853
MicroPort Scientific
6.08
-6.03
-49.83%
HK:9996
Peijia Medical Ltd.
3.77
-2.23
-37.17%
HK:1302
LifeTech Scientific Corporation
1.47
-0.54
-26.87%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.28
-4.67
-78.49%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
0.98
-1.76
-64.23%
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Corporate Events
Shanghai HeartCare Proposes New Board Term and Adds Non-Executive Director
Oct 26, 2026
Shanghai HeartCare Medical Technology Corporation Limited has initiated the process to form its third session of the board of directors, as the current second session is due to expire in November 2026. The proposed new board will comprise nine dir...
Shanghai HeartCare Ties New H Share Incentive Grant to Aggressive Revenue Growth Targets
Sep 21, 2026
Shanghai HeartCare Medical Technology Corporation Limited has granted 30,000 H share awards, equal to about 0.10% of its issued H shares, to a single employee under its 2025 H Share Incentive Scheme. The awards carry no issue price and are structu...
Shanghai HeartCare Grants Performance-Tied H Share Awards to Boost Growth
Sep 14, 2026
Shanghai HeartCare Medical Technology Corporation Limited, a Hong Kong-listed cardiovascular medical technology provider, is deepening its focus on talent retention and performance-driven culture through equity incentives. The company operates in ...
Shanghai HeartCare Details Voting Results and Governance at 2026 Second EGM
Sep 3, 2026
Shanghai HeartCare Medical Technology Corporation Limited reported that its 2026 second extraordinary general meeting was duly convened in Shanghai in accordance with PRC company law and its articles of association, with all directors attending ei...
Shanghai HeartCare Delivers Robust Interim Growth on Expanding Stroke Device Adoption
Aug 31, 2026
Shanghai HeartCare Medical Technology reported strong interim results for the six months ended June 30, 2026, with revenue rising 56.9% to RMB291 million and gross profit climbing 64.3% amid margin expansion. Net profit attributable to shareholder...
Shanghai HeartCare Sets August Board Meeting to Review Interim Results and Dividend
Aug 19, 2026
Shanghai HeartCare Medical Technology Corporation Limited has scheduled a board meeting for August 31, 2026 to review and approve the interim results for the six months ended June 30, 2026 for the company and its subsidiaries. The board will also ...
Shanghai HeartCare Plans A Share Issue and Sci-Tech Board Listing
Aug 14, 2026
Shanghai HeartCare Medical Technology Corporation Limited plans to issue up to 7,025,592 A shares and seek a listing on the Sci-Tech Board of the Shanghai Stock Exchange, subject to shareholder approval at an extraordinary general meeting and clea...
Shanghai HeartCare Seeks Shareholder Approval for Sci-Tech Board A-Share Issuance
Aug 14, 2026
Shanghai HeartCare Medical Technology Corporation Limited is a PRC-based medical technology company specializing in cardiovascular solutions, with existing H-share listing in Hong Kong and plans to broaden its investor base. The group aims to leve...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.